A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine

PHASE3CompletedINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

June 18, 2020

Primary Completion Date

June 11, 2024

Study Completion Date

June 11, 2024

Conditions
Chronic MigraineEpisodic Migraine
Interventions
DRUG

Atogepant 60 mg

Tablets containing 60 mg atogepant

Trial Locations (24)

790-0925

Takanoko Hospital /ID# 232723, Matsuyama

918-8503

Fukuiken Saiseikai Hospital /ID# 232988, Fukui-shi

003-0003

Duplicate_Higashi Sapporo Neurology and Neurosurgery Clinic /ID# 232710, Sapporo

658-0064

Konan Medical Center /ID# 232922, Kobe

310-0015

Mito Kyodo General Hospital /ID# 232990, Mito

892-0842

Atsuchi Neurosurgical Hospital /ID# 232907, Kagoshima

259-1193

Duplicate_Tokai University Hospital /ID# 233071, Isehara-shi

211-8588

Fujitsu Clinic /ID# 232717, Kawasaki-shi

780-8011

Umenotsuji Clinic /ID# 232675, Kochi

982-0014

Sendai Headache and Neurology Clinic Medical Corporation /ID# 232677, Sendai

350-0495

Saitama Medical University Hospital /ID# 233017, Iruma-gun

338-8577

Saitama Neuropsychiatric Institute /Id# 232711, Saitama-shi

420-0853

Japanese Red Cross Shizuoka Hospital /ID# 232992, Shizuoka

321-0293

Duplicate_Dokkyo Medical University Hospital /ID# 232995, Shimotsuga-gun

182-0006

Niwa Family Clinic /ID# 232713, Chofu-shi

151-0051

Duplicate_Tokyo Headache Clinic /ID# 232715, Shibuya-ku

160-8582

Keio University Hospital /ID# 233030, Shinjuku-ku

400-0124

Duplicate_Nagaseki Headache Clinic /ID# 232719, Kai-shi

730-0031

DOI Internal Medicine-Neurology Clinic /ID# 232722, Hiroshima

732-0822

Hiroshima Neurology Clinic /ID# 232720, Hiroshima

892-0844

Tanaka Neurosurgical Clinic /ID# 232884, Kagoshima

600-8811

Tatsuoka Neurology Clinic /ID# 232912, Kyoto

556-0017

Tominaga Hospital /ID# 232909, Osaka

108-0075

Shinagawa Strings Clinic /ID# 232908, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY